Ultragenyx Pharmaceutical (RARE) Profit After Tax (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Profit After Tax for 14 consecutive years, with -$185.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 22.52% year-over-year to -$185.0 million; the TTM figure through Mar 2026 stood at -$608.9 million (down 10.85% YoY), while the FY2025 annual figure was -$575.0 million, down 1.05% from the prior year.
• Profit After Tax fell to -$185.0 million in Q1 2026 per RARE's latest filing, from -$128.6 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$115.0 million in Q2 2025 and bottomed at -$245.1 million in Q3 2022.
• Historically, Profit After Tax has averaged -$155.5 million across 5 years, with a median of -$152.3 million in 2022.
• Annual changes were most pronounced in 2022 — Profit After Tax slumped 235.77% — and 2023, when it jumped 34.87%.
• Ultragenyx Pharmaceutical's Profit After Tax stood at -$151.8 million in 2022, then increased by 18.63% to -$123.6 million in 2023, then slipped by 7.81% to -$133.2 million in 2024, then advanced by 3.49% to -$128.6 million in 2025, then plunged by 43.91% to -$185.0 million in 2026.
• Business Quant data shows RARE's Profit After Tax at -$185.0 million in Q1 2026, -$128.6 million in Q4 2025, and -$180.4 million in Q3 2025.